Francesca Barone Sells 13,534 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) insider Francesca Barone sold 13,534 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total value of $97,715.48. Following the completion of the transaction, the insider now directly owns 110,673 shares of the company’s stock, valued at approximately $799,059.06. The trade was a 10.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Francesca Barone also recently made the following trade(s):

• On Wednesday, January 8th, Francesca Barone sold 13,673 shares of Candel Therapeutics stock. The stock was sold at an average price of $8.22, for a total transaction of $112,392.06.

Candel Therapeutics Stock Down 13.4 %

Shares of NASDAQ CADL traded down $1.03 during midday trading on Friday, hitting $6.66. 1,899,373 shares of the company’s stock were exchanged, compared to its average volume of 1,683,500. The firm has a market capitalization of $216.32 million, a PE ratio of -3.85 and a beta of -1.20. Candel Therapeutics, Inc. has a 12 month low of $1.16 and a 12 month high of $14.60. The company’s 50 day moving average price is $6.58 and its 200 day moving average price is $6.27.

Hedge Funds Weigh In On Candel Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. HB Wealth Management LLC raised its position in shares of Candel Therapeutics by 54.1% in the fourth quarter. HB Wealth Management LLC now owns 87,300 shares of the company’s stock valued at $696,000 after purchasing an additional 30,642 shares during the period. Barclays PLC grew its stake in Candel Therapeutics by 327.1% in the 3rd quarter. Barclays PLC now owns 28,688 shares of the company’s stock valued at $199,000 after buying an additional 21,971 shares during the last quarter. Geode Capital Management LLC raised its holdings in Candel Therapeutics by 12.8% in the 3rd quarter. Geode Capital Management LLC now owns 448,997 shares of the company’s stock valued at $3,112,000 after acquiring an additional 51,111 shares during the period. State Street Corp raised its holdings in Candel Therapeutics by 4.1% in the 3rd quarter. State Street Corp now owns 492,005 shares of the company’s stock valued at $3,410,000 after acquiring an additional 19,207 shares during the period. Finally, Atom Investors LP acquired a new stake in Candel Therapeutics during the third quarter worth approximately $103,000. 13.93% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $19.00 price objective (up from $11.00) on shares of Candel Therapeutics in a report on Wednesday, December 18th.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.